Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
about
Discoidin Domain Receptors: Potential Actors and Targets in CancerDifferences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese populationCharting Immune Signaling Proteomes En Route to New Therapeutic Strategies.Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer.Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.MTOR inhibitor-based combination therapies for pancreatic cancer.Lung squamous cell carcinoma associated with hypoparathyroidism with sensorineural deafness and renal dysplasia syndrome: a case report.Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells
P2860
Q26751157-7A04DEAD-2264-4FF0-9775-9823510AC184Q26786594-B4BFC528-870F-4D2B-9FB6-220C6984B8BEQ35815990-32106E8D-940D-42C9-B64F-AEA99B715C40Q36063032-2D37145E-C85E-46C8-9B82-B32FBA02EB83Q36146337-A24B99D7-5379-4A21-867A-9286D3E0C29CQ37566368-AD698982-B117-46DA-BE19-6914FB0C4352Q38756969-5B2A36C6-088E-4D2B-804E-96518CBE25E9Q38757884-EB89095F-8C02-42E3-B05D-C04338DE1161Q38849817-9225F403-9381-4750-86F0-ACC5A580D6A7Q41108643-64717A68-5927-4D83-8344-7A020D218C53Q47285613-1FA2426C-EE21-4878-AAC5-84BB93AD34FBQ48536576-C96D5289-11E0-49ED-9C67-2B69E7D75127Q49560871-78912725-26A9-4DB7-A87F-B5213E20FA75Q55313166-EED0A018-3AE2-4D3E-82B9-9AD2BAAF6BB0Q58573393-753B7EA5-8577-4F7B-BD89-41AB153E03FF
P2860
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adaptive responses to dasatini ...... ells harboring DDR2 mutations.
@ast
Adaptive responses to dasatini ...... ells harboring DDR2 mutations.
@en
type
label
Adaptive responses to dasatini ...... ells harboring DDR2 mutations.
@ast
Adaptive responses to dasatini ...... ells harboring DDR2 mutations.
@en
prefLabel
Adaptive responses to dasatini ...... ells harboring DDR2 mutations.
@ast
Adaptive responses to dasatini ...... ells harboring DDR2 mutations.
@en
P2093
P2860
P1433
P1476
Adaptive responses to dasatini ...... cells harboring DDR2 mutations
@en
P2093
Eric B Haura
Fumi Kinose
January M Watters
John M Koomen
Kate Fisher
Lanxi Song
Yian Ann Chen
P2860
P304
P356
10.1158/0008-5472.CAN-14-0505
P407
P577
2014-10-27T00:00:00Z